The objective of this study was to analyze CD34 + cell recovery and T cell depletion (TCD) achieved in CD34 + cell grafts using either immunoadsorption or immunomagnetic methods applied to leukapheresis products from healthy donors. We also wanted to determine the kinetics of engraftment and incidence and severity of graft-versus-host disease (GVHD) after allogeneic transplantation of selected CD34 + cells. HLA-identical sibling donors received G-CSF. After leukapheresis, peripheral blood progenitor cells were selected using immunoadsorption (Ceprate SC) (n = 38) or immunomagnetic (Isolex 300) (n = 24) methods. Sixty-two patients, with a median age of 42 years (range 17-60) diagnosed with hematological malignancies were conditioned with either cyclophosphamide and total body irradiation (n = 43) or busulphan and cyclophosphamide (n = 19). GVHD prophylaxis consisted of cyclosporin A (CsA) and prednisone (n = 48), CsA alone (n = 11) and CsA and methotrexate (n = 3). The median yield and purity of CD34 + cells after the procedure was 65 and 66% with immunoadsorption, and 48 and 86% with immunomagnetic method, respectively. The median number (range) of CD34 + cells infused into the patients was 3.5 ؋ 10 6 /kg (1-9.6). The median number (range) of CD3 + cells administered was 0.4 ؋ 10 6 /kg (0.01-2) using immunoadsorption and 0.14 ؋ 10 6 /kg (0.03-2.5) using immunomagnetic methods. Neutrophil recovery Ͼ500 and Ͼ1000/l was achieved at a median (range) of 13 days (8-22) and 14 days (9-31), respectively. Platelets recovered to Ͼ20 000 and Ͼ50 000/l at a median (range) of 13 days (0-128) and 18 days (0-180), respectively. Two patients developed graft failure. Acute GVHD in patients at risk was clinical grade 0 (n = 43), I (n = 8), II (n = 4) and III (n = 1). No patient developed acute GVHD grade IV. Chronic GVHD was limited in two cases and extensive in four cases. The actuarial probability of acute GVHD II-IV was 10% (95% CI, 1-19%), and of extensive chronic GVHD was 12% (95% CI, 11-13%). The cumulative incidence of transplantrelated mortality was 12.6%, and this figure was 9% at 6 months. In conclusion, with the immunomagnetic procedure, a lower recovery and higher purity of CD34 + cells, and stronger TCD is obtained as compared to immunoadsorption (P = 0.008, P Ͻ 0.0001 and P = 0.0002, respectively). Our results also indicate that allogeneic transplantation of selected CD34
Ex vivo T cell depletion (TCD) of the graft can effectively prevent graft-versus-host disease (GVHD) in allogeneic bone marrow transplantation (allo-BMT). 1 This procedure is also being performed in allogeneic transplantation of peripheral blood progenitor cells (allo-PBT). [2] [3] [4] [5] [6] [7] The clinical application of TCD in allo-PBT is of interest since, whereas the incidence of acute GVHD (aGVHD) in allo-PBT is not higher than expected in allo-BMT, [8] [9] [10] [11] the incidence of chronic GVHD (cGVHD) might be greater. [12] [13] [14] Moreover, G-CSF mobilized peripheral blood progenitor cells (PBPC) offer the opportunity to obtain easily a great number of hematopoietic progenitor cells and accessory cells for graft engineering.
Several techniques have been developed for depleting T cells from human marrow allografts, 1 including counterflow centrifugation, lectin agglutination and the use of MoAb directed against T lymphocytes. Most of them are timeconsuming and difficult to standardize amongst different transplantation centers. With recent progress in cell separation technology, simple, automated and reproducible methods of positively selecting CD34
+ hematopoietic progenitors are available. Selected CD34 + cells are able to reconstitute all lineages after myeloablative chemotherapy in humans. 15, 16 The two CD34 + stem cell selection systems adopted in clinical use are based on either biotin-avidin immunoadsorption (Ceprate SC) 17 or indirect immunomagnetic beads (Isolex 300). 18 Most clinical trials of TCD in allo-PBT by means of CD34 + positive selection (allo-PBT/CD34 + ) have been accomplished with the former method, [3] [4] [5] [6] [7] and few data about the use of immunomagnetic 520 CML = chronic myeloid leukemia; ALL = acute lymphoblastic leukemia; AML = acute myeloblastic leukemia; CLL = chronic lymphocytic leukemia; NHL = non-Hodgkin lymphoma; MM = multiple myeloma; RAEBt = refractory anemia with excess of blasts in transformation; a = first complete remission or first chronic phase in CML; b = disease chemoresistant or in relapse; Cy = cyclophosphamide (120 mg/kg); TBI = total body irradiation; Bu = busulfan (16 mg/kg); CsA = cyclosporin A; PDN = methylprednisolone; c 3 mg/kg ev from day Ϫ1, maintaining blood levels of 250-400 ng/ml; d 0.5 mg/kg day +7 to +14, 1 mg/kg day +15 to +28, tapering the doses afterwards; e days +1, +3, +6.
approach for TCD in allo-PBT are available. 2 Whereas in some allo-PBT/CD34
+ studies severe aGVHD occurred in a significant proportion of patients, 3, 4 suggesting that a more vigorous TCD should be mandatory to effectively prevent GVHD, we and others have reported a low incidence of this complication. [5] [6] [7] 19 All these studies are preliminary and include a small number of patients.
We employed immunoadsorption and immunomagnetic CD34
+ selection techniques for allo-PBT/CD34 + in 62 patients. The aim of this study was to analyze: (1) the yield and purity of CD34 + cells and TCD achieved with both methods; (2) the kinetics of engraftment; and (3) the incidence and severity of GVHD. Our data suggest that a lower recovery and higher purity of CD34 + cells, and stronger TCD is obtained with the immunomagnetic method. Allo-PBT/CD34
+ was associated with a rapid engraftment and low incidence of severe GVHD. Table 2 ): In 32 cases the first leukapheresis product was stored at 4°C overnight without shaking and pooled the day after with the second apheresis product. PBPC were then selected by positive selection of CD34 + cells using an immunoadsorption biotin-avidin column. In one case, showing very poor mobilization, two further aphereses were processed in the same manner. In five cases, only one apheresis and one column was used.
Isolex 300 method (n = 24) ( Table 2 ): In 13 cases one apheresis and one immunomagnetic column was used; in 11 donors two aphereses were done, in nine cases using one column and in two cases using two columns. In the 62 cases cell graft preparation was infused, without previous cryopreservation, as the sole source of progenitor cells. Immunophenotyping was performed with a FACScan flow cytometer (Becton Dickinson Immunocytometry System, San Jose, CA, USA). The antibodies used, all from Becton Dickinson, were: 8G12-PE (HPCA-2/CD34), HLe-1-FTIC (CD45), Leu-M3-PE (CD14), Leu-4-FTIC (CD3), Leu-3a-FTIC (CD4), Leu-2a-PE (CD8), Leu-19-PE (CD56) and PE-and FTIC-conjugated irrelevant isotype-specific antibodies. CD34 + cells were quantified as follows: from the analysis of forward and 90°side scatter a gate was established to include all lymphocytes and mononuclear cells, excluding platelets and red blood cells. Controls were set on the basis of those gated cells. A second gate was established on high CD34 + immunofluorescence and low side scatter. To analyze the number of CD34 + cells, a total of 300 000 events was acquired from peripheral blood and apheresis product samples, and 10 000 events from the immunoselected CD34 + cells samples. 
Patients
All consecutive patients submitted to allo-PBT/CD34 + (excluding second transplant) from HLA-identical sibling donors in nine Spanish hospitals between March 1995 and February 1997 have been included. The main characteristics of the patients are shown in Table 1 . The first day of CD34 + selected transfusion was considered as day 0. The cyclosporin A (CsA) dose was reduced if renal function was impaired, regardless of CsA blood levels. CsA was given orally as soon as oral mucositis disappeared, and was stopped by day 180 after transplantation. The diagnosis and grading of aGVHD and cGVHD were established according to conventional criteria. 20 Transplant-related mortality (TRM) was defined as death due to causes other than neoplastic relapse. Detailed written informed consent was obtained from all donors and patients before beginning the procedure. This study was approved by institutional review committees and by the Spanish Health Department.
Statistical methods
Student's t-test with two-sided P values, 2 with continuity correction, and Fisher's exact test (two tail) were used when indicated. A cumulative incidence study was applied to analyze TRM. 21 Actuarial curves were obtained by the KaplanMeier method and statistically compared using the MantelCox test. These statistical studies were performed by means of SPSS 6.1 (1994) statistical software.
Results

Donors
G-CSF administration was well tolerated except for moderate bone pain and headache occurring in most of the donors. Leukaphereses were performed without complications. Six of the 62 (9.7%) patients required a central-venous line, which was placed without complications.
Positive selection of CD34
+ cells
The original allo-PBT/CD34 + cohort consisted of 66 cases; cell clumping of the graft occurred during Isolex 300 procedure (chymopapain was used for bead release) in four of them. The very low recovery of CD34 + cells in these four cases disqualified the use of the CD34 + grafts, and unmanipulated aphereses were infused. These patients were excluded from the study. The number of CD34 + and CD3
+ cells before and after the procedure is shown in Table 3 . A lower recovery and higher purity of CD34 + cells, as well as stronger CD3
+ cell elimination was obtained with the immunomagnetic procedure as compared to immunoadsorption (P = 0.008, P Ͻ 0.0001 and P = 0.0002, respectively). The yield was influenced by the number of CD34 + cells loaded into the immunoadsorption column. Thus, depending on whether the number of CD34 + cells was lower or higher than 8.7 ϫ 10 6 /kg, the recovery was 70 vs 48%, respectively (P = 0.01). The median number of CD34 + cells infused into the patients was 3.5 ϫ 10 6 /kg (range 1-9.6). Nine patients (14.5%) received a quantity of CD34 + cells lower than 2 × 10 6 /kg, 28 patients (45.5%) received 2-4 × 10 6 /kg, and in 25 patients (40%), the quantity was equal or superior to 4 × 10 6 /kg. The median number of CD3 + cells administered in the whole group was 0.3 ϫ 10 6 /kg (range 0.02-2.5). Of the 60 cases for whom the number of CD3 + cells infused was available, in 50 cases (83.3%) the final graft contained a quantity of T cells equal to or lower than 0.5 ϫ 10 6 /kg, and in 10 cases (17.6%) the graft contained more than 0.5 × 10 6 CDD3 + cells/kg (immunoadsorption n = 9, immunomagnetic n = 1).
Kinetics of engraftment
Two patients (immunoadsorption n = 1, immunomagnetic n = 1) developed graft failure; both received cyclophosphamide (Cy) (120 mg/kg) and total body irradiation (TBI) (13 Gy in four fractions) as the conditioning regimen. In one of them, 5.2 ϫ 10 6 /kg CD34 + cells were infused and showed, after an initial rapid donor cell engraftment, an autologous reconstitution 1 month after transplant; this patient is alive and well after a follow-up of 14 months. The donor of the second case was a renal transplant recipient and was receiving CsA before and during leukapheresis. patient died with unsuccessful engraftment 60 days after the second graft infusion. The kinetics of engraftment and analysis of factors that could influence it in the remaining 60 cases is shown in Tables 4 and 5 , respectively. Posttransplant administration of G-CSF was associated with a faster neutrophil recovery (500 and 1000/l, P = 0.001 in both cases) and with a slower recovery to Ͼ20 000/l platelets (P = 0.04). There was no significant difference in the kinetics of engraftment irrespective of the type of conditioning regimen (TBI + Cy vs Bu + Cy) and the type of procedure (immunoadsorption vs immunomagnetic). Although a certain positive correlation between the number of CD34 + cells infused and neutrophil engraftment was observed, the association was not statistically significant. Our data also show that patients receiving у4.6 ϫ 10 6 /kg experienced faster Ͼ50 000/l platelet recovery than those receiving Ͻ4.6 ϫ 10 6 /kg (P = 0.03) ( Table 5) .
Graft-versus-host disease
The incidence of aGVHD and cGVHD in patients at risk is shown in Table 6 . The median follow-up of all patients who survived more than 100 days (eligible for chronic GVHD evaluation) was 6 months (range 102-728 days). The actuarial probability for aGVHD clinical grade II-IV and clinical grade III-IV of the whole group was 10% (95% CI, 1-19%) and 2% (95% CI, 1.4-2.4%), respectively. The actuarial probability of extensive cGVHD was 12% (95% CI, 11-13%). The number of both CD3 + cells and CD34 + cells, the type of procedure (immunoadsorption vs immunomagnetic), the age of the patients, and the relation female (donor) to male (recipient) did not significantly affect the incidence of aGVHD. After a median follow-up of 6 months (range 0.5-24), 11 patients (18%) relapsed, and six patients (9.7%) died in remission (GVHD n = 2, pneumonia n = 2, pulmonary hemorrhage n = 1, thrombotic thrombocytopenic purpura n = 1). Only two patients died in remission during the first 100 days post-transplant. The cumulative incidence of TRM was 12.6% (Figure 1 ), and this figure was 10% at 6 months.
Discussion
The high number of T cells contained in leukaphereses was greatly reduced by both methods. Thus, approximately 3 
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+ cells A Urbano-Ispizua et al 523 log TCD was achieved by immunoadsorption and 3.5 logs by the immunomagnetic technique, which corresponds to a median of 0.4 ϫ 10 6 /kg and 0.14 ϫ 10 6 /kg T cells infused to the patients, respectively (Table 3) . Several reports suggest that in HLA-identical sibling recipients these quantities of T lymphocytes could maintain a certain degree of GVL effect and facilitate the engraftment [22] [23] [24] [25] without triggering GVHD. [24] [25] [26] [27] A more vigorous TCD would be necessary in a mismatched or haploidentical transplantation, 28 and probably in an unrelated setting. 29 The numbers of T lymphocytes we infused into the patients were similar to those infused in two allo-PBT/CD34
+ series 5, 6 and were lower than those reported in two others. 3, 4 The increased number of aphereses required in some studies to obtain a high target dose of CD34 + cells 4 increases the absolute number of T cells in the final graft. Rising G-CSF doses 30 would improve the absolute CD34 + cell numbers in the final inoculum maintaining a low quantity of T cells. 5 
A greater yield of CD34
+ cells with a sacrifice of population purity was observed with the immunoadsorption technique as compared to immunomagnetic bead selection. The recovery of hematopoietic progenitor cells from PBPC grafts using immunoadsorption ranges broadly amongst different transplant centers at between 70% 7,31,32 and 35%. 3, 5, 6 Our results show that the total number of CD34 + cells loaded into the column influences the final recovery. Thus, depending on whether the number of CD34
+ cells ϫ 10 6 /kg was lower or higher than 8.7, the recovery was 70 vs 48%, respectively (P = 0.01). Another factor that could influence the final CD34 + cell recovery is the platelet count in the harvest. 32 Schreiner et al, 32 using a specific buffer and low speed centrifugation steps to remove platelets and to prevent platelet aggregation obtained a median recovery of 98% in nine cases. Like other authors, we have observed that the purity of CD34 + cells in the final graft is 65% with immunoadsorption 3,5-7,31-33 and greater than 85% with the immunomagnetic method. 17, [34] [35] [36] Although the lower purity of CD34 + fractions resulting from immunoadsorption does not seem to be of clinical relevance in allo-PBPT/CD34 + , it implies that the use of the immunomagnetic system might be more appropriate for purging autologous PBPC grafts, ex vivo expansion and gene therapy. With Isolex 300, however, the bead release with chymopapain from the target CD34 + cells remains a problem. In fact, 66 allo-PBT/CD34 + patients were initially enrolled in this study and in four of them, cell clumping of the graft occurred during the Isolex 300 procedure, which disqualified the CD34 + cell grafts. The use of PR34 + TM stem cell releasing agent instead of chymopapain to avoid this problem seems promising. 37 One of the main advantages of allo-PBT is the faster kinetics of engraftment as compared to allo-BMT. [8] [9] [10] [11] 38 Graft manipulation and infusion of CD34 + selected cells did not appear to delay neutrophil and platelet engraftment, regardless of the method employed (Tables 4 and 5 ) and is similar to that observed after unmanipulated allo-PBT. [8] [9] [10] [11] 38 The absence of a deleterious effect of TCD on the kinetics of engraftment might be related to the high number of CD34 + cells infused into the patients. 39 Furthermore, the infusion of high numbers of hematopoietic progenitor cells seems to improve survival in TCD allotransplant. 40 A doseresponse relationship between the number of CD34 + cells infused and the rate of neutrophil and platelet recovery has been defined in the autologous setting. [41] [42] [43] In the allogeneic context, factors such as ABO barriers or minor antigenic differences between donor and recipient, or the use of MTX for GVHD prophylaxis can diminish the influence of the number of CD34 + cells on the kinetics of engraftment. A clear correlation between the number of CD34
+ cells infused and the neutrophil engraftment could not be demonstrated in this study. However, patients receiving у4.6 ϫ 10 6 /kg experienced faster Ͼ50 000/l platelet recovery than those receiving Ͻ4.6 ϫ 10 6 /kg (P = 0.03) ( Table 5 ). Our analysis also supports the observation that G-CSF administration after allo-PBT/CD34
+ not only accelerates neutrophil engraftment but also slows platelet recovery, results also reported in unmanipulated allo-PBT. 11 The clinical benefit of TCD is compromised by increased rates of graft failure. 44 Although the use of more intensive pretransplant immunosuppression overcomes this complication 44 it also leads to higher TRM. Increasing the number of CD34
+ cells could decrease rates of graft failure and make the more intensive conditioning regimen unnecessary. In our study, patients conditioned with TBI + Cy had identical kinetics of engraftment to those conditioned with Bu + Cy, confirming previous data. 5 This could be of interest, since some authors consider that Bu + Cy would not be immunosuppressive enough to allow engraftment in a TCD graft from a matched sibling donor. 45 The aim of the use of positive selection of CD34
+ cells was to reduce the graft T cell content under the threshold of risk for GVHD. The precise number of T cells that can trigger clinical GVHD in HLA-identical sibling transplantation is presently unknown. The usual reference is 0.1 ϫ 10 6 /kg clonable T lymphocytes when no post-transplant immunosuppression is used, 46 but this number could be slightly higher, eg between 0.1 and 0.5 ϫ 10 6 /kg [22] [23] [24] [25] [26] when CsA is used post-transplant. In this study, patients received a median of 0.3 ϫ 10 6 /kg CD3 + cells. The actuarial incidence of aGVHD grade III-IV of the whole group was only 2%. Finke et al 5 and Brugger et al 6 have also reported a very low incidence of GVHD infusing a similar amount of T cells (0.4 and 0.5 ϫ 10 6 /kg, respectively). By contrast, Link et al 3 and Bensinger et al 4 reported an incidence of aGVHD grade III-IV of 50%; of note, patients from these later series received a higher number of T cells: 1.35 and 0.7 ϫ 10 6 /kg, respectively. Bensinger et al 47 in another cohort of older patients with advanced malignancies receiving 0.08 ϫ 10 6 CD3 + cells/kg observed that only two out of 20 cases experienced aGVHD grade III-IV. All these data together would suggest that the infusion of an inoculum with a number of T cells lower than 0.5 ϫ 10 6 /kg would be associated with a low incidence of severe aGVHD, and that more vigorous TCD would be not necessary for its prevention in HLA-identical sibling donor transplantation. For total abrogation of any degree of aGVHD, 'total' TCD instead of 'partial' TCD would be mandatory but probably at the cost of increasing graft failure, losing the GVL effect, and experiencing more delayed immune reconstitution. Indeed, GVHD is a complex process influenced not only by the number of T cells infused, but also by other factors, such as age and clinical status of the patient, and sex parity of donor and recipient. 48 Post-transplant immunosuppression seems necessary when 'partial' TCD allotransplant is performed. 24, 26 The need for adding prednisone or MTX to CsA is unclear. Although in this study there were no differences between the group receiving CsA alone and that receiving CsA plus prednisone, Finke et al 5 administering CsA alone observed that three out of 10 patients developed aGVHD grade II. The low incidence of aGVHD observed in some series of allo-PBT/CD34
+ has been related to the fact of having cryopreserved the CD34 + graft. 5 However, in this study the final grafts were not cryopreserved. Although the followup in this series was too short to assess cGVHD, it must be noted that the actuarial probability for extensive cGVHD of the whole group was 12% (95% CI, 11-13%). This is of interest since, whereas the incidence of aGVHD in allo-PBT seems to be similar (or even lesser) to that seen in allo-BMT, [8] [9] [10] [11] preliminary results suggest that the incidence of cGVHD might be increased. [12] [13] [14] Thus, allo-PBT/CD34
+ would exploit the advantages of peripheral blood as a source of hematopoietic progenitor cells (ie safety of the donor and quick engraftment) without a higher incidence of cGVHD.
The major goals of this study were to determine the differences between immunoadsorption and immunomagnetic techniques with respect to recovery, purity and TCD capacity, as well as to obtain clinical data about engraftment and GVHD in allo-PBT/CD34
+ . Using the immunomagnetic technique, a lower recovery and higher purity of CD34 + cells and stronger TCD is obtained in the graft preparation as compared to immunoadsorption (P = 0.008, P Ͻ 0.0001 and P = 0.0002, respectively). Our results also indicate that allogeneic transplantation of selected CD34
+ cells is associated with a rapid engraftment and with a low incidence of severe GVHD. Although it is too early to assess survival in this study, only six out of 62 patients died in remission, the cumulative incidence of TRM being 12.6%. These results are encouraging, taking into consideration the fact that 26% of the cases were older than 50 years, and that in 44%, the disease was advanced or chemoresistant at the time of transplantation.
